Michal Shteinberg

Oct 22, 2024 | emjreviews.com | Pieter Goeminne |Michal Shteinberg

Introduction The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by symptoms such as recurrent bronchial infection, sputum production, chronic cough, dyspnoea, and exacerbations.1 Bronchiectasis prevalence estimates range by geographical region, gender, and age, with indications that prevalence is rising.2-4 One of the most common causes of bronchiectasis, as shown in 16,963 patients in the European Multicentre Bronchiectasis...

Sep 10, 2024 | erj.ersjournals.com | James Chalmers |Michal Shteinberg |Marcus A. Mall |Anne O'Donnell

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Feb 22, 2024 | erj.ersjournals.com | Michal Shteinberg

FootnotesConflict of interest: M.

Jan 31, 2024 | err.ersjournals.com | Mariana Conceição |Michal Shteinberg |James Chalmers

IntroductionBronchiectasis is associated with chronic respiratory bacterial infection, which perpetuates airway inflammation [1, 2]. Pseudomonas aeruginosa is the most frequent organism in severe bronchiectasis [3–7]. Chronically infected patients with P. aeruginosa have worse quality of life, increased exacerbations and hospital admissions, and poorer prognosis [8–10]. In cystic fibrosis patients, the role of P.